Scilex Holding Company Partners with National Pharmacy Chain to Bring GLOPERBA to Wider Market
PALO ALTO, Calif. Feb. 28, 2024 - Scilex Holding Company (Nasdaq: SCLX, Scilex or Company) has announced a groundbreaking partnership with a leading national pharmacy chain to make its innovative non-opioid pain management product, GLOPERBA, widely available in stores across the United States. This strategic collaboration aims to address the overwhelming demand for effective treatments for acute and chronic pain in the country.
GLOPERBA, an FDA-approved prophylactic treatment for painful gout flares in adults, is anticipated to hit the U.S. market in the first half of 2024. The shared commitment of Scilex and the pharmacy chain will ensure that GLOPERBA reaches maximum accessibility, reaching patients who are in dire need of pain relief.
Recognizing the urgent need for alternative pain management solutions, Scilex has dedicated its efforts to acquiring, developing, and commercializing non-opioid treatments for all forms of pain. GLOPERBA, with its proven efficacy and safety profile, has emerged as a significant player in this space and has the potential to revolutionize pain management practices.
By partnering with a leading national pharmacy chain, Scilex takes a significant step towards expanding the reach of GLOPERBA to a larger population. With the extensive store presence and distribution network of the pharmacy chain, GLOPERBA will be readily available to patients in most stores across the U.S. ensuring quick access to this much-needed pain relief treatment.
Furthermore, the increased manufacturing of GLOPERBA is a proactive measure taken by Scilex to meet anticipated demand and ensure adequate stocking in the distribution center. This move reflects the company’s determination to provide a seamless supply chain and timely access to GLOPERBA, thereby alleviating the burden of pain for countless individuals.
The Scilex Holding Company’s partnership with a leading pharmacy chain marks a significant milestone in the journey to combat pain and improve the quality of life for patients nationwide. The collaboration between these two major healthcare entities shines a light on the urgent need for non-opioid pain management solutions and exemplifies the innovative spirit driving the industry forward.
Comments